← FDA DRUG APPROVALS

FDA ANDA · ANDA084579

RESERPINE AND HYDROCHLOROTHIAZIDE

Sponsor: BARR

APPLICATION
ANDA084579
TYPE
ANDA
ORIGINAL APPROVAL
1975-09-30
LATEST ACTION
1992-02-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

RESERPINE AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 50MG, RESERPINE 0.125MG · TABLET · ORAL

Approval history

1992-02-14Labeling · Supplement 37AP
1991-01-22Labeling · Supplement 36AP
1989-08-23Labeling · Supplement 35AP
1989-06-16Labeling · Supplement 33AP
1989-03-24Labeling · Supplement 34AP
1975-09-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →